SEP 10, 2026 · PHASE 1/2 TRIAL
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
ClinicalTrials.gov
This is a Phase 1/2 clinical trial registration with no posted results; it describes a planned early-phase study of a novel combination therapy in advanced solid tumors, designed primarily to establish safety and tolerability.
Reported
Planned enrollment184
Study phasePhase 1 and Phase 2
Primary outcome (Phase 1 and Phas…Number of participants with AEs, SAEs, and…